Business news, event reports and more from Cellusion PR team

Visit to Celregen in China


Cellusion COO Joji Hayashida, CDO Nobuyuki Imai, and CMC Director Shinji Yoshizaki visited Celregen Therapeutics Ltd. (“Celregen”) in Shanghai, China.

Celregen is a cell regenerative medicine platform company and a member of the leading Chinese pharmaceutical company Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Celllusion has an exclusive license agreement in the Greater China region for Celregen to develop, manufacture and commercialize CLS001*.

This time, we visited China in conjunction with the regularly held Joint Steering Committee, to discuss and exchange opinions on future development policies and various issues, and to tour Celregen’s offices and laboratories.

Comments from Joji Hayashida, EVP & COO, Cellusion
Through this visit, we felt the enthusiasm of Celregen’s staff for their commitment to bring a new treatment to bullous keratopathy patients suffering from the shortage of donor corneas in the Greater China region as soon as possible.
We are also confident that through mutual visits and other exchanges, our relationship as collaborative partners has deepened.
Furthermore, the tour of Celregen’s facility and the exchange of opinions made us realize the difference between the dynamism of the Shanghai area, which has one of the world’s leading startup ecosystems, and our current situation, and reaffirmed the need for further efforts and dedication for Cellusion to grow into a startup that can compete on a global scale.

We will continue to push forward with the global expansion of CLS001 in close cooperation with our collaborative partners.

CLS001 is alternative cell to corneal endothelial cells produced by efficiently differentiating iPS cells, which can be differentiated into various types of cells, based on Cellusion’s proprietary technique. Cellusion is promoting the development of CLS001 as a therapeutic regenerative medicine product for bullous keratopathy, which accounts for more than half of the corneal transplant cases, by combining CECSi Cells(Corneal Endothelial Cell Substitute from iPS Cells) made from iPS cells with excellent proliferative properties” and “a simple injection cell delivery procedure without needs of human expertise.” Cellusion is also advancing preparations for company-sponsored clinical trials in Japan, as well as preparations for global clinical trials.

From third left: Cellusion CDO Nobuyuki Imai, CMC Director Shinji Yoshizaki, COO Joji Hayashida

Back to the List